Erin D. Michos, MD, MHS

Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.

Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.

Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.

An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.

Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; provide an overview of upcoming treatment options for managing hypercholesterolemia.

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.

Experts in endocrinology and cardiology review novel agents in the pipeline for the management of hypercholesterolemia and ASCVD.

Erin D. Michos, MD, MHS, leads a discussion on selecting the appropriate patient populations for the use of bempedoic acid when managing atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Christie Ballantyne, MD, leads a discussion on the use of bempedoic acid for the management of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia as seen in the CLEAR studies.

Erin D. Michos, MD, MHS; Christie Ballantyne, MD; Yehuda Handelsman, MD; and Paul S. Jellinger, MD, MACE, address the use of combination therapies and statin intolerance in patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Matthew J. Budoff, MD; Paul S. Jellinger, MD, MACE; Erin D. Michos, MD, MHS; Yehuda Handelsman, MD; and Christie Ballantyne, MD, comment on the use of icosapent ethyl in reducing atherosclerotic cardiovascular disease (ASCVD) events and managing lipid disorders.

Health care experts discuss use of older agents to control atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia in certain patient populations.

Christie Ballantyne, MD, leads a discussion on the efficacy and safety of bempedoic acid for the management of ASCVD and hypercholesterolemia.